deltatrials
Suspended NA INTERVENTIONAL 2-arm NCT04963920

A RCT to Assess the Performance of CytoSorb for Shock Reversal in Patients With Vasoplegic Septic Shock (PROCYSS)

A Prospective, Randomized, Multicenter, Single-blind, Controlled Study to Assess the Performance of the Cytosorb® 300 ml Device for Shock Reversal in Patients With Vasoplegic Septic Shock

Sponsor: BRAHMS GmbH

Conditions Septic Shock
Interventions Cytosorb® 300 ml
Updated 18 times since 2021 Last updated: Jul 31, 2025 Started: Jan 30, 2022 Primary completion: Feb 28, 2027 Completion: May 31, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Suspended

Recruitment for the study is currently on hold to allow for a protocol amendment. This revision aims to align the study design with changes in clinical practice since the trial's initiation.

This NA trial investigates Septic Shock and is currently suspended. BRAHMS GmbH leads this study, which shows 18 recorded versions since 2022 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Sep 2021 – ~Mar 2022 · 6 months · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Sep 2022 · 4 months · monthly snapshot~Sep 2022 – ~Dec 2022 · 3 months · monthly snapshot~Dec 2022 – ~Feb 2023 · 2 months · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~Sep 2023 · 5 months · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Feb 2024 · 4 months · monthly snapshot~Feb 2024 – ~Jun 2024 · 4 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Sep 2025 · 11 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

18 versions recorded

  1. Sep 2025 — Present [monthly]

    Suspended NA

    Status: Recruiting → Suspended

  2. Oct 2024 — Sep 2025 [monthly]

    Recruiting NA

  3. Sep 2024 — Oct 2024 [monthly]

    Recruiting NA

  4. Aug 2024 — Sep 2024 [monthly]

    Recruiting NA

  5. Jul 2024 — Aug 2024 [monthly]

    Recruiting NA

▶ Show 13 earlier versions

  1. Jun 2024 — Jul 2024 [monthly]

    Recruiting NA

  2. Feb 2024 — Jun 2024 [monthly]

    Recruiting NA

  3. Oct 2023 — Feb 2024 [monthly]

    Recruiting NA

  4. Sep 2023 — Oct 2023 [monthly]

    Recruiting NA

  5. Apr 2023 — Sep 2023 [monthly]

    Recruiting NA

  6. Mar 2023 — Apr 2023 [monthly]

    Recruiting NA

  7. Feb 2023 — Mar 2023 [monthly]

    Recruiting NA

  8. Dec 2022 — Feb 2023 [monthly]

    Recruiting NA

  9. Sep 2022 — Dec 2022 [monthly]

    Recruiting NA

  10. May 2022 — Sep 2022 [monthly]

    Recruiting NA

  11. Apr 2022 — May 2022 [monthly]

    Recruiting NA

  12. Mar 2022 — Apr 2022 [monthly]

    Recruiting NA

    Status: Not Yet Recruiting → Recruiting

  13. Sep 2021 — Mar 2022 [monthly]

    Not Yet Recruiting NA

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • BRAHMS GmbH
  • CytoSorbents Europe GmbH
  • MedInnovation GmbH
Data source: CytoSorbents Europe GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Berlin, Germany , Dresden, Germany , Emden, Germany , Erfurt, Germany , Essen, Germany , Frankfurt am Main, Germany , Greifswald, Germany , Göttingen, Germany , Hamburg, Germany , Herford, Germany and 6 more locations